imm-6-415
·Code: IMM-6-415
imm-6-415: developed by 1 company · 1 clinical trial tracked.
imm-6-415 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect imm-6-415 to IMRX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could imm-6-415 → IMRX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Advanced Solid Tumor (Phase 1)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Immuneering Corp (IMRX) Advanced Solid Tumor (Phase 1) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations
Primary endpoint: Phase 1/2a: Adverse Events
Interventionalopen30 enrolledStarted 2024-02Completion 2025-045 sites · United StatesImmuneering Corporation
Frequently asked questions
Who is developing imm-6-415?
imm-6-415 is being developed by Immuneering Corp.
How many clinical trials involve imm-6-415?
BioSniper tracks 1 clinical trial involving imm-6-415.